Education
About Us
Working with TipRanks
Follow Us
Crescent Biopharma (CBIO)
NASDAQ:CBIO
CBIO Stock Chart & Stats
$9.51
--
Market closed
$9.51
--
Day’s Range― - ―
52-Week Range$9.10 - $37.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)145.41K
Market Cap
$262.06M
Enterprise Value$131.86M
Total Cash (Recent Filing)$133.26M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding27,556,767
10 Day Avg. Volume163,515
30 Day Avg. Volume145,412
Financial Highlights & Ratios
PEG Ratio-13.03
Price to Book (P/B)302.15
Price to Sales (P/S)0.00
P/FCF Ratio-51.61
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue4.31
Enterprise Value/Gross Profit4.55
Enterprise Value/Ebitda-2.04
Forecast
1Y Price Target
$30.14Price Target Upside216.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual Property And Commercial UpsideEstablished patent protection into the 2040s and positioning as a fast-follower to a validated bispecific format support upside potential if clinical data validate the approach and market recognition narrows valuation gaps with larger peers.
Pipeline Diversification And Combination StrategyIn-house antibody-drug conjugate programs paired with CR-001 create multiple combination options, providing development flexibility and potential synergistic clinical benefits that can differentiate the portfolio.
Strategic Partnership And Global DevelopmentCross-licensing and the Kelun collaboration grant ex-Greater China rights and enable coordinated parallel trials, allowing simultaneous data generation in China and ex-China and strengthening global development execution.
Bears Say
Clinical Development RiskPrograms are early-stage and require clinical proof of benefit before therapeutic and commercial potential can be confirmed, making initial trial readouts binary catalysts that could significantly affect valuation.
Financing And Dilution RiskHigh cash burn and a limited cash runway increase the likelihood of needing additional financing, which could dilute existing shareholders and pressure the stock.
Crescent Biopharma News
CBIO FAQ
What was Crescent Biopharma’s price range in the past 12 months?
Crescent Biopharma lowest stock price was $9.10 and its highest was $37.00 in the past 12 months.
What is Crescent Biopharma’s market cap?
Crescent Biopharma’s market cap is $262.06M.
When is Crescent Biopharma’s upcoming earnings report date?
Crescent Biopharma’s upcoming earnings report date is Apr 30, 2026 which is in 80 days.
How were Crescent Biopharma’s earnings last quarter?
Crescent Biopharma released its earnings results on Nov 06, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.959 by $0.689.
Is Crescent Biopharma overvalued?
According to Wall Street analysts Crescent Biopharma’s price is currently Undervalued.
Does Crescent Biopharma pay dividends?
Crescent Biopharma pays a Quarterly dividend of $0.24 which represents an annual dividend yield of N/A. See more information on Crescent Biopharma dividends here
What is Crescent Biopharma’s EPS estimate?
Crescent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Crescent Biopharma have?
Crescent Biopharma has 27,556,767 shares outstanding.
What happened to Crescent Biopharma’s price movement after its last earnings report?
Crescent Biopharma reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.959. Following the earnings report the stock price went up 5.39%.
Which hedge fund is a major shareholder of Crescent Biopharma?
Currently, no hedge funds are holding shares in CBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crescent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.14 (216.93% Upside)
$30.14 (216.93% Upside)
Insider Transactions
Bought Shares
Worth $18.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.9%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.89%
12-Months-Change
Fundamentals
Return on Equity
-51.70%
Trailing 12-Months
Asset Growth
544.72%
Trailing 12-Months
Company Description
Crescent Biopharma
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
CBIO Stock 12 Month Forecast
Average Price Target
$30.14
▲(216.93% Upside)
Technical Analysis
Compugen
―
Fate Therapeutics
―
Orchestra BioMed Holdings
―
Fractyl Health, Inc.
―
Actuate Therapeutics, Inc.
―